晚期鼻咽癌同步放化疗临床研究  

Clinical study of concurrent chemoradiotherapy for advanced nasopharyngeal carcinoma

作　　者：岳丽娟[1] 侯新丽[1] 

机构地区：[1]汉中市中心医院肿瘤内科,陕西汉中723000

出　　处：《中国医学前沿杂志（电子版）》2015年第7期119-121,共3页Chinese Journal of the Frontiers of Medical Science(Electronic Version)

摘　　要：目的探讨同步放化疗治疗晚期鼻咽癌的临床效果。方法选择本院放疗科和肿瘤内科2007年8月至2009年8月收治的晚期鼻咽癌患者200例为研究对象,随机分为研究组与对照组,每组各100例。对照组患者给予常规分次放疗,研究组患者给予常规分次放疗同步顺铂(DDP)+5-氟尿嘧啶(5-FU)方案化疗,比较两组患者近期疗效、放疗局部及全身不良反应发生情况及近/远期生存率。结果研究组患者近期临床有效率为96.0%(96/100),显著高于对照组[87.0%(87/100)](P<0.05)。两组患者颈部皮肤损害、口腔黏膜损害及鼻腔黏膜损害发生等级、白细胞减少及血小板减少发生率比较差异均无显著性(P>0.05)。研究组患者治疗后1、3、5年生存率均高于对照组(P<0.05)。结论晚期鼻咽癌患者同步放化疗,能够改善临床效果及患者预后,延长生存期,且具有较高的安全性,值得临床推广应用。Objective To investigate the clinical curative effect of concurrent chemoradiotherapy for advanced nasopharyngeal carcinoma. Method 200 patients with advanced nasopharyngeal carcinoma treated in our hospital from August 2007 to August 2009 were selected as the research objects, were randomly divided into study group and control group, 100 cases in each group. Control group patients received conventional fractionated radiotherapy, study group patients received conventional fractionated radiotherapy plus DDP ＋5-FU regimen chemotherapy. Short-term curative effect, radiation therapy, local and systemic adverse reactions and short-term, long-term survival rate of the two groups were compared. Result Short-term curative effect rate was 96.0%（96/100） in study group, significantly higher than control group [87.0%（87/100）]（P〈0.05）. The differences of the two groups of patients with neck skin damage, the damage of the oral mucosa and nasal mucosa damage levels, leukocytopenia and thrombocytopenia were not significant（P〉0.05）. After treatment, 1, 3, 5 year survival rates of study group were higher than control group（P〈0.05）. Conclusion For advanced nasopharyngeal carcinoma concurrent chemoradiotherapy can improve the clinical effect and prognosis of patients, prolong the survival period, and has high safety, worthy of clinical application.

关 键 词：鼻咽癌 同步放化疗 疗效 生存率 

分 类 号：R739.63[医药卫生—肿瘤]